A pooled analysis of the studies found that about two-thirds of participants receiving the drug retatrutide experienced at least a 50% reduction in knee pain, compared with 38% of those receiving a placebo. Experimental GLP-1 drug retatrutide shows meaningful knee pain reduction in overweight osteoarthritis patients, amid ongoing trials and FDA review.